CSIMarket
 


X4 Pharmaceuticals Inc  (XFOR)
Other Ticker:  
 

Cumulative X4 Pharmaceuticals Inc's Quick Ratio for Trailing Twelve Months Period

XFOR's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

XFOR Quick Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth -11.74 % 1.14 % 32.08 % 63.16 % 125.98 %
Y / Y Cash & cash equivalent Growth 77.43 % 198.26 % 40.61 % 48.82 % 4.53 %
Quick Ratio for Trailing Twelve Months Period 5.87 4.95 3.9 3.78 3.66
Total Ranking # 423 # 559 # 758 # 900 # 969
Seq. Current Liabilities Growth 15.23 % 15.27 % -13.34 % -23.31 % 32.03 %
Seq. Cash & cash equivalent Growth 0.26 % 51.28 % -23.26 % 52.42 % 68.55 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis X4 Pharmaceuticals Inc Cash & cash equivalent average soared by 77.43% in III. Quarter year on year, while Current Liabilities increased to $ 24 millions, this led to increase in in X4 Pharmaceuticals Inc's Quick Ratio for Trailing Twelve Months Period to 5.87, Quick Ratio for Trailing Twelve Months Period remained below X4 Pharmaceuticals Inc average.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 67 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than X4 Pharmaceuticals Inc. While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about XFOR
Quick Ratio XFOR in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 68
Sector # 292
S&P 500 # 406


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
11.55 6.27 3.46
(Jun 30 2020)   (Sep 30 2022)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Quick Ratio for Trailing Twelve Months Period
Protara Therapeutics Inc   15.84 
Apogee Therapeutics inc   15.75 
Fusion Pharmaceuticals Inc   15.74 
Revolution Medicines Inc   15.53 
Aura Biosciences Inc   15.21 
Creative Medical Technology Holdings Inc   14.62 
Compass Therapeutics Inc   14.35 
Crispr Therapeutics Ag  13.99 
Anavex Life Sciences Corp   13.65 
Kymera Therapeutics Inc   13.35 
Voyager Therapeutics Inc   12.73 
Achilles Therapeutics Plc  12.56 
Cardiff Oncology inc   12.40 
Rubius Therapeutics Inc   11.94 
Ikena Oncology Inc   11.74 
Springworks Therapeutics Inc   11.12 
Aim Immunotech Inc   10.97 
Scholar Rock Holding Corp  10.56 
Invivyd Inc   10.51 
Allogene Therapeutics inc   10.40 
Century Therapeutics inc   10.35 
Monte Rosa Therapeutics Inc   10.29 
Ambrx Biopharma Inc   10.26 
Organovo Holdings Inc   10.07 
Avrobio Inc   10.06 
Caribou Biosciences Inc   9.83 
Iteos Therapeutics Inc   9.70 
Athira Pharma Inc   9.52 
Solid Biosciences Inc   9.45 
Vectivbio Holding Ag  8.95 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com